A Northwestern University study has uncovered a novel biomarker for schizophrenia and identified a synthetic protein that could treat its debilitating cognitive symptoms. Researchers found reduced levels of the brain protein Cacna2d1 in schizophrenia patients compared to healthy controls, leading to overactive brain circuits. They created SEAD1, a synthetic version of this protein, which corrected abnormal activity and behavioral issues in mouse models without negative side effects.

This biomarker-therapeutic approach could revolutionize treatment by targeting the specific subgroup of patients most likely to respond. The team now aims to develop a blood biomarker for patient selection and optimize SEAD1 for clinical trials, potentially offering a weekly injection similar to diabetes treatments. This breakthrough addresses the critical gap in therapies for cognitive deficits like disorganized thinking and executive dysfunction, which severely impact patients' ability to function independently.